The clinical features of older patients with lung cancer in comparison with their younger counterparts

Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiratory investigation 2019-01, Vol.57 (1), p.40-48
Hauptverfasser: Ogino, Hirokazu, Hanibuchi, Masaki, Sakaguchi, Satoshi, Toyoda, Yuko, Tezuka, Toshifumi, Kawano, Hiroshi, Kakiuchi, Soji, Otsuka, Kenji, Saijo, Atsuro, Azuma, Masahiko, Nokihara, Hiroshi, Goto, Hisatsugu, Nishioka, Yasuhiko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 48
container_issue 1
container_start_page 40
container_title Respiratory investigation
container_volume 57
creator Ogino, Hirokazu
Hanibuchi, Masaki
Sakaguchi, Satoshi
Toyoda, Yuko
Tezuka, Toshifumi
Kawano, Hiroshi
Kakiuchi, Soji
Otsuka, Kenji
Saijo, Atsuro
Azuma, Masahiko
Nokihara, Hiroshi
Goto, Hisatsugu
Nishioka, Yasuhiko
description Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines. In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy. We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.
doi_str_mv 10.1016/j.resinv.2018.10.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2135635433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212534518301102</els_id><sourcerecordid>2135635433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</originalsourceid><addsrcrecordid>eNp9kE1LxDAQQIMoruj-A5EcvbQmTdJtL4KIXyB40XNIk4mbpW3WJFX892bp6tFcJsy8mWEeQueUlJTQ-mpTBohu_CwrQpucKglhB-ikqmhVCCbY4d-fiwVaxrgh-dWi4rQ-RgtGOG8qzk6QfV0D1r0bnVY9tqDSlCdjb7HvDQS8VcnBmCL-cmmN-2l8x1qNOlfciLUftiq46Me5nNbgAv72mcqAzjFByESKZ-jIqj7Cch9P0dv93evtY_H88vB0e_NcaNbUqWgIrxsjoCUrQlrVWso564xQtrOmMUR0jdGdMpZAxWzLNRDQLazaWnRdlw86RZfz3G3wHxPEJAcXNfS9GsFPUVaUiZoJzlhG-Yzq4GMMYOU2uEGFb0mJ3EmWGzlLljvJu2yWnNsu9humbgDz1_SrNAPXMwD5zk8HQUadFWowLoBO0nj3_4Yf6CWRxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2135635433</pqid></control><display><type>article</type><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</creator><creatorcontrib>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</creatorcontrib><description>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines. In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy. We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</description><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2018.10.003</identifier><identifier>PMID: 30448243</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Age Factors ; Aged ; Chemoradiotherapy ; Comorbidity ; Drug Therapy ; Female ; Humans ; Life Expectancy ; Lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Neoplasm Staging ; Older patients ; Prognosis ; Real-world clinical practice ; Retrospective Studies ; Standard treatments ; Survival Rate ; Treatment Outcome</subject><ispartof>Respiratory investigation, 2019-01, Vol.57 (1), p.40-48</ispartof><rights>2018 The Japanese Respiratory Society</rights><rights>Copyright © 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</citedby><cites>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</cites><orcidid>0000-0002-4637-9488 ; 0000-0002-7710-5498</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30448243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogino, Hirokazu</creatorcontrib><creatorcontrib>Hanibuchi, Masaki</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Yuko</creatorcontrib><creatorcontrib>Tezuka, Toshifumi</creatorcontrib><creatorcontrib>Kawano, Hiroshi</creatorcontrib><creatorcontrib>Kakiuchi, Soji</creatorcontrib><creatorcontrib>Otsuka, Kenji</creatorcontrib><creatorcontrib>Saijo, Atsuro</creatorcontrib><creatorcontrib>Azuma, Masahiko</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Goto, Hisatsugu</creatorcontrib><creatorcontrib>Nishioka, Yasuhiko</creatorcontrib><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><title>Respiratory investigation</title><addtitle>Respir Investig</addtitle><description>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines. In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy. We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Chemoradiotherapy</subject><subject>Comorbidity</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Life Expectancy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Older patients</subject><subject>Prognosis</subject><subject>Real-world clinical practice</subject><subject>Retrospective Studies</subject><subject>Standard treatments</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQQIMoruj-A5EcvbQmTdJtL4KIXyB40XNIk4mbpW3WJFX892bp6tFcJsy8mWEeQueUlJTQ-mpTBohu_CwrQpucKglhB-ikqmhVCCbY4d-fiwVaxrgh-dWi4rQ-RgtGOG8qzk6QfV0D1r0bnVY9tqDSlCdjb7HvDQS8VcnBmCL-cmmN-2l8x1qNOlfciLUftiq46Me5nNbgAv72mcqAzjFByESKZ-jIqj7Cch9P0dv93evtY_H88vB0e_NcaNbUqWgIrxsjoCUrQlrVWso564xQtrOmMUR0jdGdMpZAxWzLNRDQLazaWnRdlw86RZfz3G3wHxPEJAcXNfS9GsFPUVaUiZoJzlhG-Yzq4GMMYOU2uEGFb0mJ3EmWGzlLljvJu2yWnNsu9humbgDz1_SrNAPXMwD5zk8HQUadFWowLoBO0nj3_4Yf6CWRxw</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Ogino, Hirokazu</creator><creator>Hanibuchi, Masaki</creator><creator>Sakaguchi, Satoshi</creator><creator>Toyoda, Yuko</creator><creator>Tezuka, Toshifumi</creator><creator>Kawano, Hiroshi</creator><creator>Kakiuchi, Soji</creator><creator>Otsuka, Kenji</creator><creator>Saijo, Atsuro</creator><creator>Azuma, Masahiko</creator><creator>Nokihara, Hiroshi</creator><creator>Goto, Hisatsugu</creator><creator>Nishioka, Yasuhiko</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4637-9488</orcidid><orcidid>https://orcid.org/0000-0002-7710-5498</orcidid></search><sort><creationdate>201901</creationdate><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><author>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Chemoradiotherapy</topic><topic>Comorbidity</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Life Expectancy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Older patients</topic><topic>Prognosis</topic><topic>Real-world clinical practice</topic><topic>Retrospective Studies</topic><topic>Standard treatments</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogino, Hirokazu</creatorcontrib><creatorcontrib>Hanibuchi, Masaki</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Yuko</creatorcontrib><creatorcontrib>Tezuka, Toshifumi</creatorcontrib><creatorcontrib>Kawano, Hiroshi</creatorcontrib><creatorcontrib>Kakiuchi, Soji</creatorcontrib><creatorcontrib>Otsuka, Kenji</creatorcontrib><creatorcontrib>Saijo, Atsuro</creatorcontrib><creatorcontrib>Azuma, Masahiko</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Goto, Hisatsugu</creatorcontrib><creatorcontrib>Nishioka, Yasuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogino, Hirokazu</au><au>Hanibuchi, Masaki</au><au>Sakaguchi, Satoshi</au><au>Toyoda, Yuko</au><au>Tezuka, Toshifumi</au><au>Kawano, Hiroshi</au><au>Kakiuchi, Soji</au><au>Otsuka, Kenji</au><au>Saijo, Atsuro</au><au>Azuma, Masahiko</au><au>Nokihara, Hiroshi</au><au>Goto, Hisatsugu</au><au>Nishioka, Yasuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical features of older patients with lung cancer in comparison with their younger counterparts</atitle><jtitle>Respiratory investigation</jtitle><addtitle>Respir Investig</addtitle><date>2019-01</date><risdate>2019</risdate><volume>57</volume><issue>1</issue><spage>40</spage><epage>48</epage><pages>40-48</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><abstract>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines. In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy. We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30448243</pmid><doi>10.1016/j.resinv.2018.10.003</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4637-9488</orcidid><orcidid>https://orcid.org/0000-0002-7710-5498</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2212-5345
ispartof Respiratory investigation, 2019-01, Vol.57 (1), p.40-48
issn 2212-5345
2212-5353
language eng
recordid cdi_proquest_miscellaneous_2135635433
source MEDLINE; Alma/SFX Local Collection
subjects Adult
Age Factors
Aged
Chemoradiotherapy
Comorbidity
Drug Therapy
Female
Humans
Life Expectancy
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Middle Aged
Neoplasm Staging
Older patients
Prognosis
Real-world clinical practice
Retrospective Studies
Standard treatments
Survival Rate
Treatment Outcome
title The clinical features of older patients with lung cancer in comparison with their younger counterparts
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20features%20of%20older%20patients%20with%20lung%20cancer%20in%20comparison%20with%20their%20younger%20counterparts&rft.jtitle=Respiratory%20investigation&rft.au=Ogino,%20Hirokazu&rft.date=2019-01&rft.volume=57&rft.issue=1&rft.spage=40&rft.epage=48&rft.pages=40-48&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2018.10.003&rft_dat=%3Cproquest_cross%3E2135635433%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2135635433&rft_id=info:pmid/30448243&rft_els_id=S2212534518301102&rfr_iscdi=true